About MindBio Therapeutics
MindBio Therapeutics is a company based in Melbourne (Australia) founded in 2021 by Justin Hanka. MindBio Therapeutics offers products and services including MB22001. MindBio Therapeutics operates in a competitive market with competitors including Celerion, Ask Gene Pharma, Altasciences, iCardiac Technologies and Avance Clinical, among others.
- Headquarter Melbourne, Australia
- Founders Justin Hanka
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mindbio Therapeutics Corp.
-
Annual Revenue
Not available
-
Net Profit
-$1.85 M (USD)-579.22as on Jun 30, 2025
-
EBITDA
-$1.27 M (USD)-185.8as on Jun 30, 2025
-
Latest Funding Round
$987.91 K (USD), Post-IPO
Apr 01, 2026
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MindBio Therapeutics
MindBio Therapeutics is a publicly listed company on the CSE with ticker symbol MBIO in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MindBio Therapeutics
MindBio Therapeutics offers a comprehensive portfolio of products and services, including MB22001.
Microdose psychedelic treatment for major depressive disorder.
Funding Insights of MindBio Therapeutics
Investments & Acquisitions by MindBio Therapeutics
Investment portfolio details for MindBio Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MindBio Therapeutics
Detailed financials for MindBio Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mindbio Therapeutics Comparisons
Peer comparison for MindBio Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MindBio Therapeutics
MindBio Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celerion, Ask Gene Pharma, Altasciences, iCardiac Technologies and Avance Clinical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Early clinical research services are provided for drug development.
|
|
| Locked | Locked | Locked |
Biosimilars and biosuperiors are developed and commercialized in biotechnology.
|
|
| Locked | Locked | Locked |
Early phase clinical research services are provided in North America.
|
|
| Locked | Locked | Locked |
Cardiac safety testing and respiratory laboratory services are provided.
|
|
| Locked | Locked | Locked |
Clinical development services are provided to pharmaceutical clients worldwide.
|
|
| Locked | Locked | Locked |
CRO services for Phase I Clinical Trials, and Core ECG lab services for trials from Phase I to IV
|
Detailed competitors of MindBio Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mindbio Therapeutics
Complete news archive for MindBio Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MindBio Therapeutics
MindBio Therapeutics was founded in 2021 and raised its 1st funding round 3 years after it was founded.
MindBio Therapeutics is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
MindBio Therapeutics was established in 2021 and is based in Melbourne, Australia. Clinical trial services at phase I and II levels are provided, with a focus on mental health diseases within the biotechnology sector. Operations center on developing and testing treatments through structured trial protocols. The company is led by co-founder Justin Hanka, supporting research advancements in psychiatric conditions.
MindBio Therapeutics's top competitors include Celerion, Ask Gene Pharma and Altasciences.
MindBio Therapeutics offers MB22001.
Yes, MindBio Therapeutics is publicly traded on CSE under the ticker symbol MBIO.
The ticker symbol of MindBio Therapeutics is MBIO on CSE.